These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 33973194)

  • 41. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What are protective antibody responses to pandemic SARS-CoV-2?
    Henderson JP
    J Clin Invest; 2020 Dec; 130(12):6232-6234. PubMed ID: 33055417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody Therapy for COVID-19: Categories, Pros, and Cons.
    Zare Marzouni H; Rahbar M; Seddighi N; Nabizadeh M; Meidaninikjeh S; Sabouni N
    Viral Immunol; 2022 Oct; 35(8):517-528. PubMed ID: 36201297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coronavirus disease 2019 (COVID-19): a clinical update.
    Zhou M; Zhang X; Qu J
    Front Med; 2020 Apr; 14(2):126-135. PubMed ID: 32240462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
    Pavia CS; Wormser GP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune reactivity during COVID-19: Implications for treatment.
    Napoli C; Benincasa G; Criscuolo C; Faenza M; Liberato C; Rusciano M
    Immunol Lett; 2021 Mar; 231():28-34. PubMed ID: 33421440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.
    Tirnea L; Bratosin F; Vidican I; Cerbu B; Turaiche M; Timircan M; Margan MM; Marincu I
    Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33799535
    [No Abstract]   [Full Text] [Related]  

  • 49. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
    Tang J; Grubbs G; Lee Y; Golding H; Khurana S
    Clin Infect Dis; 2022 Jan; 74(2):327-334. PubMed ID: 33861337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Therapeutic Journey of Potential Drugs Against COVID-19.
    Ali F; Hussain S; Zhu YZ
    Mini Rev Med Chem; 2022; 22(14):1876-1894. PubMed ID: 33845740
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial.
    Huygens S; Hofsink Q; Nijhof IS; Goorhuis A; Kater AP; Te Boekhorst PAW; Swaneveld F; Novotný VMJ; Bogers S; Welkers MRA; Papageorgiou G; Rijnders BJ; Heijmans J
    J Infect Dis; 2023 Jan; 227(2):206-210. PubMed ID: 35921542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose.
    Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1155-1162. PubMed ID: 35838042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of SARS-CoV-2 in paediatrics : what is the evidence to date?].
    Fougère Y; Rohr M; Vetter P; Wagner N
    Rev Med Suisse; 2021 Feb; 17(726):344-348. PubMed ID: 33599410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comprehensive review on potential therapeutics interventions for COVID-19.
    Chugh H; Awasthi A; Agarwal Y; Gaur RK; Dhawan G; Chandra R
    Eur J Pharmacol; 2021 Jan; 890():173741. PubMed ID: 33227287
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunization against severe acute respiratory syndrome Coronavirus 2: an overview.
    El-Masry EA
    Afr Health Sci; 2021 Dec; 21(4):1574-1583. PubMed ID: 35283984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model
    Bohländer F; Riehl D; Weißmüller S; Gutscher M; Schüttrumpf J; Faust S
    Front Immunol; 2021; 12():700429. PubMed ID: 34177967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy.
    Casadevall A; Joyner MJ; Pirofski LA
    Clin Infect Dis; 2021 Aug; 73(3):e540-e542. PubMed ID: 32805024
    [No Abstract]   [Full Text] [Related]  

  • 58. Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients.
    Pal P; Ibrahim M; Niu A; Zwezdaryk KJ; Tatje E; Robinson WR; Ko L; Satyavarapu I; Jones WE; Nachabe A; Luk A; Mushatt DM; Halvorson K; Denson JL; Smith CC; Simeone F; Davis G; Gill SK; McDougal A; Vigh AS; Peterson TG; Ning B; Hu T; Socola F; Robinson J; Safah H; Saba NS
    Transfus Med; 2021 Jun; 31(3):217-220. PubMed ID: 33073895
    [No Abstract]   [Full Text] [Related]  

  • 59. Cytosorb filter: An adjunct for survival in the COVID-19 patient in cytokine storm? a case report.
    Rizvi S; Danic M; Silver M; LaBond V
    Heart Lung; 2021; 50(1):44-50. PubMed ID: 33041058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia.
    Abe T; Izumo T; Ueda A; Hayashi M; Ishibashi Y
    CEN Case Rep; 2021 Feb; 10(1):42-45. PubMed ID: 32715376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.